Back to results
US 2006/0233751 A1Published application
Regulatory T cells suppress autoimmunity
AssigneeThe Regents of the University of California
InventorsJeffrey Bluestone, Qizhi Tang, Emma Masteller
Life of this patent
Estimating the term…
Abstract
The invention provides methods for producing an autoantigen-specific regulatory T cell enriched composition, and resultant compositions and methods of use.
Claims20
1-21. (canceled)
A composition comprising:
- a population of natural cells wherein at least 50% of said cells of said composition are autoantigen-specific regulatory T cells.
A method of adoptive cellular immunotherapy, the method comprising the steps of:
- extracting a mixed population of T cells from a patient diagnosed with diabetes mellitus and presenting an indication of impaired glucose homoeostasis selected from fasting plasma glucose (FPG), post-prandial glucose (PPG), and glucose tolerance (GTT);
- isolating from the population a subpopulation comprising >98% CD4+CD25+ T cells (Treg cells) by negative and positive immuno-selection and cell sorting;
- expanding the Treg cells of the subpopulation at least 100-fold by contacting the subpopulation with effective amounts of (i) a TCR/CD3 activator selected from a multivalent antibody and ligand for TCR/CD3;
- (ii) a TCR costimulator activator selected from a multivalent antibody and ligand for CD28;
- and (iii) IL-2, wherein the effective amount of IL-2 is 200 to 2500 IU IL-2/ml, to obtain ex vivo expanded Treg cells;
- introducing into the patient 107 to 1011 of the ex vivo expanded Treg cells;
- and
- detecting a resultant improvement in the impaired glucose homoeostasis.
5 more elements
Dependencies are inferred from the claim text.